Identification of an unusual combination of actionable mutations through genomic profiling in a child with an aggressive sarcoma.
Shimaa Sherif, PhD1,2, Wouter R. L. Hendrickx, PhD1,2, Christophe M. Raynaud, PhD1, William Mifsud MD, PhD3, Davide Bedognetti, MD, PhD1,2*, Ata Ur Rehman Maaz, MD 4*.
1Tumor Biology and Immunology laboratory, Research Branch, Sidra Medicine, Doha, Qatar
2College of Health and Life Sciences, Hamad Bin Khalifa University, Qatar Foundation, Doha, Qatar
3Anatomical Pathology, Sidra Medicine, Doha, Qatar
4Pediatric Hematology and Oncology Division, Sidra Medicine, Doha, Qatar
* Correspondence to:
Ata Maaz, MD, Pediatric Hematology and Oncology Division, Sidra Medicine, Doha, Qatar, Email: amaaz@sidra.org.
Davide Bedognetti, MD, PhD, Tumor Biology and Immunology laboratory, Research Branch, Sidra Medicine, Doha, Qatar, Email: davidebedognetti@gmail.com.
Brief running title: RAS-RAF double mutations in aggressive sarcoma.
Key words: Embryonal Rhabdomyosarcoma, genomic profiling, HRAS, BRAF